According to the Census 2014, the population in the Republic of the Union of Myanmar was 51,410,000. The crude birth rate in the previous one year was estimated to be 18.9 per 1,000, giving the annual population growth rate of 0.89% between 2003 and 2014. The Ministry of Health reorganized into six departments. National non-governmental organizations and community-based organizations support health care, as well as international non-governmental organizations. Since hospital statistics by the government cover only public facilities, the information on private facilities is limited. Although there were not enough medical doctors (61 per 100,000 population), the number of medical students was reduced from 2,400 to 1,200 in 2012 to ensure the quality of medical education. The information on causes of death in the general population could not be retrieved, but some data was available from hospital statistics. Although the improvement was marked, the figures did not reach the levels set by Millennium Development Goals 4 and 5. A trial prepaid health insurance system started in July 2015, to be followed by evaluation one year later. There are many international donors, including the Japan International Cooperation Agency, supporting health in Myanmar. With these efforts and support, a marked progress is expected in the field of health care. (Source: Nagoya General of Medical Science)
The Administration of Health Department
According to the Census 2014, the population in the Republic of the Union of Myanmar was 51,410,000. The crude birth rate in the previous one year was estimated to be 18.9 per 1,000, giving the annual population growth rate of 0.89% between 2003 and 2014. The Ministry of Health reorganized into six departments. National non-governmental organizations and community-based organizations support health care, as well as international non-governmental organizations. Since hospital statistics by the government cover only public facilities, the information on private facilities is limited. Although there were not enough medical doctors (61 per 100,000 population), the number of medical students was reduced from 2,400 to 1,200 in 2012 to ensure the quality of medical education. The information on causes of death in the general population could not be retrieved, but some data was available from hospital statistics. Although the improvement was marked, the figures did not reach the levels set by Millennium Development Goals 4 and 5. A trial prepaid health insurance system started in July 2015, to be followed by evaluation one year later. There are many international donors, including the Japan International Cooperation Agency, supporting health in Myanmar. With these efforts and support, a marked progress is expected in the field of health care. (Source: Nagoya General of Medical Science)
The Administration of Health Department
Many charity hospitals are running by religious bodies and society clubs, some NGOs are also working on towards the improvements of the health in Myanmar which supports poor.
Public/Government Hospitals are established in every district of the country but most of the hospitals are far away from the reach of rural area 70% of population is living in rural areas with minimum or no medical facilities.
The Government hospitals are also using traditional or old machines and techniques of diagnostic disease. They need lots of updatation to be done in their labs and hospitals. The appearance of private hospitals in Major Cities like Yangon, Mandalay and Naypyidaw gave rise to the development of organised and well equipped labs, Some independents Labs also came into existence.
Here we are more concern with the In vitro Diagnostic devices so let us shift our focus.
The In vitro Diagnostic devices are test that detect various materials found in body fluids and tissues such as whole blood and plasma, these are used as non-invasive way to facilitate medical diagnosis, monitor treatment information that is essentials for the safe and effective use of corresponding drugs, biological product. IVDs can also allow for early and accurate diagnosis of a disease, resulting in more efficient treatment and better outcomes for patients.
IVDs are medical devices, some examples of IVDs include HIV test kit, Pregnancy Kits, Urine test strips, blood sugar monitoring system for diabetics.
IVDs are conducted in different clinical settings including hospital labs, commercial labs, blood banks, emergency rooms, ICU, Physician’s in fact at the customer’s home.
Medical Market of Myanmar is quite new in case of IVDs, no Brands or manufacturing company has their presence in market, except Roach which is also a new one. Mostly IVDs are imported from China, Japan, Hong Kong and here in Myanmar some traders who deals in IVDs they simply distributes in the hospitals and labs via direct sale or install machines on rent and sell reagents only.
Following are the major distributor of IVDs in Myanmar:
- Okkar Thiri Co.ltd.
- AMD Co. Ltd.
- JJ PUN Co. Ltd.
- Undiagnostic .Co Ltd.
- Concordia International l Co. ltd.
- ACS Myanmar Co. Ltd.
- Nanova Co Ltd.
- Biomed Myanmar
- Ever Glory Co. Ltd.
And many other small dealers are also actively dealing with IVDs.
The Brand which is popularly seen in labs is:
- Roche
- Sysmex
- Danaher
- Biomeriux
- Mind ray
- Abbott
- Siemens
- Agilent
- Sakura
Overall Market Size in 2018 is MMK 32049.8 which includes Centralized Diagnostic (64.9%)Tissue diagnostic (5.2%), Molecular diagnostic (16.6%) and Point of care (13.2%).
We found that IM (Immunoassay) Market experienced negative growth in 2018 due to health budget slash the board that year. The market is dominated by Roche as other players have less penetration in the market. Abbott has been aggressively gaining more shares in the IM market segment. A moderate growth is expected in the next 5 years, driven by the growing adoption of IM testing particularly in cities like Yangon and Mandalay. Top 5 Competitors in descending order of market share across APAC: Roche, Abbott, Danaher, Siemens and Fuji Rebio
The POC market continues to experience exceptionally high growth driven largely by infectious diseases and the government growing focus on public health. Overall, POC is still a nascent market in Myanmar, with ample room of growth. Government hospitals with limited financial capacity for centralized system, trend to rely on POC analysers. Top 5 competitors in depending order of market share across APAC. Danaher, Abbott, Siemens, Roche and Werfen.
The Molecular diagnostic market is poised to grow at a high rate owing to increasing interest in the field and the government’s commitment to eradicate infectious disease. Other non – Virology segments with in this market remain largely underdeveloped due to high cost and low test volume. In fact very few facilities provide molecular diagnostic testing, namely LUDU Molecular and Diagnostic Centre, SML Healthcare, and to some extent, the newly established Grand Hantha Hospital. Top % competitors in descending order of market share across APAC: Roche, Grifols, Da An (CN), Qiagen and Amoydx (CN).
Most of the Lab in Myanmar lack advanced staining technologies and skilled pathologist, most of the Tissue diagnostic procedure are done manually. High test volume, shortage of skilled manpower and lack of automation present as unmet need in this space. Top 5 competitors in descending order of market share APAC: Roche, Danaher, Thermofisher, Maixin (CN) and Agilent.
Scope for New Players
Myanmar is emerging market for all sorts of business and warmly welcome investors, many foreign trade rule and agencies are in existence and many more are in pipeline to upgrade the health industry of country and improve the health of people. Many private hospital and commercial labs are operated in which government also has little interference.
Medical / Nursing colleges and institutes are also working on same, earlier there was no insurance facility in fact now a days there are no medical insurance active in the country patient have to bear all the expanses by their own. Country need to focus on this also and spread awareness about importance of health policy.